The Safety and Effectiveness of 4R-CHOP+4R vs 6R-CHOP+2R in Newly Diagnosed Patients With DLBCL in Low Risk

The Safety and Effectiveness of Four Courses of R-CHOP Plus Four Courses of Rituximab Versus Six Courses of R-CHOP Plus Two Courses of Rituximab in the Treatment of Naive, Low-risk, Non-mass Diffuse Large B-cell Lymphoma: a Multi-center, Prospective, Randomized Controlled Study

Trial Details

NCT ID
NCT05018520
Phase
PHASE3
Sponsor
Ruijin Hospital
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • Six Courses of R-CHOP Plus Two Courses of Rituximab
  • Four Courses of R-CHOP Plus Four Courses of Rituximab
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Pathologically confirmed CD20 positive DLBCL based on 2016 WHO classification who achieved CR after 4 cycles of RCHOP therapy (examined by PET-CT, …
  • Treatment naïve
  • Age ≥ 14 or ≤75 years
  • non-mass (The length of the lesion\<7.5cm)

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →